Gilead Sciences has entered into a licence agreement with Tibotec Pharmaceuticals to develop and market a single-tablet regimen comprising Prezista (darunavir), Emtriva (emtricitabine, GS7340) and cobicistat, a pharmacoenhancer.
Under the agreement, Gilead will be responsible for the formulation, manufacturing, registration, distribution and commercialisation of the single-tablet regimen worldwide, while Tibotec will co-detail the single-tablet regimen in certain major markets.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Gilead Sciences chief scientific officer Norbert Bischofberger said that his is the first time the company is developing a protease inhibitor-containing single-tablet regimen, due to the small milligram size of GS 7340.
"We are pleased to once again be partnering with Tibotec to advance and simplify HIV treatment for patients," Bischofberger added.
Gilead plans to begin a Phase II study of GS 7340, an anti-HIV agent, in 2012.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
